Looking to sell Orbital Therapeutics stock or options?
Orbital Therapeutics, a developer of an RNA therapeutics platform, is committed to incorporating a critical mix of both established and emerging technologies and delivery methods. The company's aim is to progress a comprehensive and transformative collection of ribonucleic acid therapeutics that can be used to treat a variety of human diseases. This includes areas such as vaccines, immunomodulation, protein replacement, and regenerative medicine, thereby providing patients with contemporary treatment options.
The Invus Group, Alexandria Venture Investments, Redmile Group, iGlobe Partners, Abu Dhabi Growth Fund, ARCH Venture Partners, Heritage Medical Systems, Rsquared, Agent Capital, Moore Capital Management, Rellim Capital Management, Moore Strategic Ventures, Andreessen Horowitz, Newpath Partners, Casdin Capital, Exor.